FrancophonIA/ELRC3.0 huggingface dataset:
English: Helicobacter Test INFAI 75 mg powder for oral solution 13C-urea
Estonian: Helicobacter INFAI test 75 mg suukaudse lahuse pulber 13C uurea
English: 1 Jar (10 ml volume, polystyrene with polyethylene snap cap) containing 45 mg 13C-urea powder for oral solution
Estonian: Purk (mahuga 10 ml, polüstüreenist koos polüetüleenist klõpsatava korgiga) sisaldab 45 mg 13C-uurea suukaudse lahuse pulbrit
English: Thirty minutes after administration of the test solution (point 7), collect the 30-minute-value samples in the two containers which are left in the test package (Label “Sampling time: 30-minute-value”), as described under steps 3 to 4.
Estonian: 30 minutit pärast testlahuse manustamist (punkt 7) koguge 30-minuti väärtuse proovid kahte konteinerisse, mis veel testikomplekti jäänud on (sildiga “Proovivõtmise aeg: 30-minuti väärtus”), nagu kirjeldatud punktides 3 kuni 4.
English: Now the second breath sample container (labelled “sampling time: 00-minute-value”) has to be filled up with breath in the same way as described above.
Estonian: Nüüd täitke teine hingamisproovi konteiner (sildiga “proovivõtmise aeg: 00-minuti väärtus”), järgides sama hingamisprotseduuri.
English: Helicobacter Test INFAI for children of the age 3-11 may be used for in vivo diagnosis of gastroduodenal Helicobacter pylori infection: - for the evalutation of the success of eradication treatment, or, - when invasive tests cannot be performed, or - when there are discordant results arising from invasive tests.
Estonian: - eradikatsiooniravi edukuse hindamiseks või - kui invasiivseid uuringuid ei saa teha või - kui invasiivsete testide tulemused on vastuolulised.
English: • By continuously breathing the patient must pull out the straw and immediately close the breath bag with its stopper.
Estonian: • Samal ajal hingamist jätkates tuleb kõrs välja tõmmata ja koheselt hingamiskott selle korgiga sulgeda.
English: How to store Helicobacter Test INFAI for children of the age 3-11
Estonian: Kuidas Helicobacter INFAI testi lastele vanuses 3…11 aastat säilitada
English: 50 jars containing 75 mg 13C-urea powder for oral solution
Estonian: 50 purki sisaldab 75 mg 13C-uurea suukaudse lahuse pulber
English: 30 minutes after the test solution has been taken (point 7), the “30-minute-value” samples are collected in the breath sample containers labelled “sampling time: 30-minute-value” as described under point 3 and 4.
Estonian: 30 minutit peale testlahuse manustamist (punkt 7) koguge 30-minuti väärtuse proovid hingamisproovi konteineritesse (Silt: “proovivõtmise aeg: 30-minuti väärtus”), nagu kirjeldatud punktides 3 ja 4.
English: Use the bar-code labels marked “30-minute-value” for these samples.
Estonian: Nende proovide jaoks kasutage ribakoodidega silte, kuhu on märgitud “30-minuti väärtus”.
English: • The stopper is removed from one of the breath sample containers described under point 2
Estonian: • Kasutage kõrt ja hingamisproovi konteinerit (vt punkt 2), millel on märgitud
English: How to take Helicobacter Test INFAI for children of the age 3-11
Estonian: Kuidas Helicobacter INFAI testi lastele vanuses 3…11 aastat kasutada
English: Jar (10 ml volume, polystyrene with polyethylene snap cap) containing 75 mg 13C-urea powder for oral solution
Estonian: Purk (mahuga 10 ml, polüstüreenist koos polüetüleenist klõpsatava korgiga) sisaldab 75 mg 13C-uurea suukaudse lahuse pulbrit
English: • Sample Inlet
Estonian: • Proovi sisestamine
English: Thirty minutes after administration of the test solution (point 6), collect the 30-minute-value sample in the breath bag, which is left in the test package (Label “Sampling time: 30-minutevalue”), as described under step 3.
Estonian: 30 minutit pärast testlahuse manustamist (punkt 6) koguge 30-minuti väärtuse proov hingamiskotti, mis veel testikomplekti jäänud on (sildiga “Proovivõtmise aeg: 30-minuti väärtus”), nagu kirjeldatud punktis 3.
English: There is insufficient data on the reliability of the Helicobacter Test INFAI for children of the age 3-11 for recommending its use in patients with removal of parts of the stomach.
Estonian: Helicobacter INFAI testi lastele vanuses 3…11 aastat usaldusväärsuse kohta on selle soovitamiseks maoosade eemalduse läbiteinud patsientidele ebapiisavalt andmeid.
English: • Now the patient breathes gently through the straw into the breath bag.
Estonian: • Nüüd hingake õrnalt läbi kõrre hingamiskotti.
English: How to take Helicobacter Test INFAI
Estonian: Kuidas Helicobacter INFAI testi kasutada
English: 6.3 Shelf-life
Estonian: 6.3 Kõlblikkusaeg
English: 1 jar containing 45 mg 13C-urea powder for oral solution
Estonian: 1 purk, sisaldab 45 mg 13C-uurea suukaudse lahuse pulber 4 hingamiskotti
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING INTERMEDIATE CARTON, PACK SIZE 50
Estonian: SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED SISEPAKEND, 50 PURKI
English: (If the sample tube remains open for more than 30 seconds, the test result might be falsified.)
Estonian: (Kui proovitoru jääb avatuks kauemaks kui 30 sekundit, võivad testi tulemused olla valed).
English: • Remove the stopper from one of the breath sample containers (tube or breath bag),
Estonian: • Eemaldage ühelt proovikonteinerilt (toru või hingamiskott) kork, pakkige lahti kõrs ja asetage kõrs konteinerisse.
English: • The straw and the breath bag labelled “sampling time: 00-minute-value” are taken from the test set.
Estonian: • Võtke kõrs ja hingamiskott sildiga “Proovivõtmise aeg: 00-minuti väärtus”
English: Helicobacter Test INFAI 75 mg powder for oral solution
Estonian: Helicobacter Test INFAI 75 mg suukaudse lahuse pulber.
English: containing 75 mg 13C-urea powder for oral solution 2 Data sheet for patient documentation 3 Package leaflet
Estonian: 1 purk, sisaldab 75 mg 13C-uurea suukaudse lahuse pulbrit 2 hingamiskotti
English: • Hold the sample tube upright and stick the bar-code label marked “00-minute-value”
Estonian: • Hoidke hingamiskotti ülespidi ja kleepige hingamiskotile ribakoodiga silt, kuhu on märgitud “00-minuti väärtus”
English: Ask your doctor, if fasting is a problem, for example for diabetic patients.
Estonian: Kui söömata olek on probleem (näiteks suhkurtõve haigetel), pidage nõu oma arstiga.
English: C-urea powder for oral solution Labelled sample glass- or plastic- containers for sampling, storing and transporting the breath samples for analysis: Sampling time: 00-minute-value Sampling time: 30-minute-value 3 Bendable straw for collection of the breath samples into the corresponding sample containers 4 Data sheet for patient documentation 5 Package leaflet 6 Page of barcode labels and sticker
Estonian: Purk (mahuga 10 ml, polüstüreenist koos polüetüleenist klõpsatava korgiga) sisaldab 75 mg 13C-uurea suukaudse lahuse pulbrit hingamiskotid: Proovivõtmise aeg: 00-minuti väärtus Proovivõtmise aeg: 30-minuti väärtus 3 Painutatav kõrs hingamisproovide kogumiseks vastavatesse hingamiskottidesse 4 Andmeleht patsiendi info dokumenteerimiseks 5 Pakendi infoleht, ribakoodiga sildid ja kleebis
English: • By continuously breathing the patient must pull out the straw and immediately close the sample tube with its stopper.
Estonian: • Samal ajal hingamist jätkates tuleb kõrs välja tõmmata ja koheselt proovitoru selle korgiga sulgeda.
English: • stomach ulcer
Estonian: Suukaudse lahuse pulber
English: • The straw and sample tubes labelled “sampling time: 00-minute-value” are taken from the test set.
Estonian: • Võtke kõrs ja proovituubid, millel on märgitud “proovivõtmise aeg: 00-minuti väärtus”
English: Content of the test kit with 1 jar:
Estonian: 1 purgiga test-komplekt sisaldab:
English: Pharmacotherapeutic group: Other diagnostic agents, ATC code: VO4CX For the amount of 45 mg 13C-urea, which is administered per unit in the course of the breath test, no pharmacodynamic activity is described.
Estonian: Hingamistesti käigus ühiku kohta manustatava 45 mg 13C-uurea suhtes ei ole kirjeldatud farmakodünaamilist aktiivsust.
English: and place the unwrapped straw into the breath sample container.
Estonian: • Nüüd hingake õrnalt läbi kõrre hingamisproovi konteinerisse.
English: Endemic areas are areas where the disease occurs regularly throughout the year.
Estonian: Endeemilised piirkonnad on piirkonnad, kus haigus esineb tihti kogu aasta jooksul.
English: The risk of severe disease is higher in people who have been infected a second time.
Estonian: Raske haiguse risk on suurem inimestel, kes on nakatunud teist korda.
English: Three studies were carried out in Asia and Latin America involving over 35,000 children aged 2 to 16 years.
Estonian: Aasias ja Ladina-Ameerikas viidi läbi kolm uuringut, milles osales 35 000 last vanuses 2-16 aastat.
English: Additional studies showed that the vaccine is also effective in people aged 16 to 45 years.
Estonian: Täiendavad uuringud näitasid vaktsiini efektiivsust ka 16-45aastastel inimestel.
English: What measures are being taken to ensure the safe and effective use of Dengvaxia?
Estonian: Mis meetmed võetakse, et tagada Dengvaxia ohutu ja efektiivne kasutamine?
English: Further information on Dengvaxia can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Dengvaxia.
Estonian: Lisateave Dengvaxia kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Dengvaxia.
English: Dengvaxia's side effects are usually mild or moderate and do not last longer than three days.
Estonian: Dengvaxia kõrvalnähud on tavaliselt kerged või mõõdukad ega kesta rohkem kui kolm päeva.
English: The injection is given under the skin, preferably in the upper arm.
Estonian: Süst tehakse naha alla, eelistatavalt õlavarde.
English: Other information about Dengvaxia
Estonian: Muu teave Dengvaxia kohta
English: Dengvaxia must not be given to people with weakened immune systems, including people whose immune system has been weakened by HIV infection or medicines such as cancer medicines or high doses of corticosteroids.
Estonian: Dengvaxiat ei tohi anda nõrgenenud immuunsüsteemiga inimestele, sealhulgas inimesed, kelle immuunsüsteemi on nõrgestanud HIV-nakkus või ravimid, näiteks vähiravimid või kortikosteroidide suured annused.
English: However, a small number of patients develop severe disease, with potentially fatal bleeding and organ damage.
Estonian: Väikesel arvul patsientidel tekib siiski raske haigus koos verejooksuga, mis võib lõppeda surmaga, ja organikahjustusega.
English: As for all medicines, data on the use of Dengvaxia are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Dengvaxia kasutamise kohta pidevat järelevalvet.
English: The vaccine is given as 3 doses, 6 months apart.
Estonian: Vaktsiini manustatakse 3 annusena, mille vahele jäetakse 6 kuud.
English: Allergic reactions, which may be severe, are a very rare side effect of Dengvaxia.
Estonian: Allergilised reaktsioonid, mis võivad olla rasked, on Dengvaxia korral väga harvad kõrvalnähud.
English: Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend the body against a disease.
Estonian: Vaktsiinid n-ö õpetavad immuunsüsteemi (organismi looduslikke kaitsemehhanisme) kaitsma organismi haiguse eest.
English: What is Dengvaxia and what is it used for?
Estonian: Mis on Dengvaxia ja milleks seda kasutatakse?
English: The European Medicines Agency therefore decided that Dengvaxia's benefits are greater than its risks and it can be authorised for use in the EU in areas where dengue disease is endemic.
Estonian: Euroopa Ravimiamet otsustas, et Dengvaxia kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita dengue palaviku endeemilistes piirkondades.
English: The most common side effects with Dengvaxia (which may affect more than 1 in 10 people) are headache, injection site pain, malaise (feeling unwell), muscle pain, weakness and fever.
Estonian: Dengvaxia kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on peavalu, süstekoha valu, halb enesetunne, lihasvalu, nõrkus ja palavik.
English: There are several varieties (called serotypes) of dengue virus and Dengvaxia protects against serotypes 1, 2, 3 and 4.
Estonian: Dengue viirusel on mitu varianti (serotüübid) ja Dengvaxia kaitseb dengue viiruse serotüüpide 1, 2, 3 ja 4 eest.
English: Dengvaxia must also not be given to women who are pregnant or breastfeeding.
Estonian: Dengvaxiat ei tohi kasutada ka rasedad ega imetavad naised.
English: For more information about using Dengvaxia, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Dengvaxia kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dengvaxia have also been included in the summary of product characteristics and the package leaflet.
Estonian: Dengvaxia ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: There is no other vaccine for dengue disease and neither is there a specific treatment.
Estonian: Dengue palaviku vastu puuduvad muud vaktsiinid ja puudub ka eriravi.
English: Dengvaxia contains weakened viruses that do not cause disease.
Estonian: Dengvaxia sisaldab nõrgestatud viirusi, mis ei põhjusta haigestumist.
English: Dengvaxia can only be obtained with a prescription and should be used according to official recommendations.
Estonian: Dengvaxia on retseptivaktsiin ja seda tuleb kasutada vastavalt ametlikele soovitustele.
English: Side effects reported with Dengvaxia are carefully evaluated and any necessary action taken to protect patients.
Estonian: Dengvaxia kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: In the future, when the person comes into contact with dengue virus, these antibodies together with other components of the immune system will be able to kill the virus and help protect against the disease.
Estonian: Kui inimene puutub dengue viirusega hiljem uuesti kokku, hävitavad antikehad ja immuunsüsteemi muud komponendid viiruse ning aitavad kaitsta haiguse eest.
English: Dengvaxia (dengue tetravalent vaccine [live, attenuated])
Estonian: Dengvaxia (Dengue palaviku tetravalentne vaktsiin [nõrgestatud elusvaktsiin])
English: The company that markets Dengvaxia will provide educational material for healthcare professionals with information on the use of Dengvaxia including the need to test for previous dengue infection and how to detect early dengue disease.
Estonian: Dengvaxia turustaja annab tervishoiutöötajatele teabematerjalid Dengvaxia kasutamise teabega, sealhulgas teabega vajaduse kohta testida varasemat dengue nakkust ja teave selle kohta, kuidas tunda ära dengue palaviku algfaasi.
English: What are the risks associated with Dengvaxia?
Estonian: Mis riskid Dengvaxiaga kaasnevad?
English: However, people who have not had dengue infection in the past may have a higher risk of severe dengue disease if they become infected with the virus after vaccination with Dengvaxia.
Estonian: Inimestel, kes aga ei ole varem nakatunud, võib raske kuluga dengue palaviku risk olla suurem, kui nad nakatuvad viirusega pärast Dengvaxiaga vaktsineerimist.
English: Dengvaxia is only for use in people from 9 to 45 years of age who have been infected with dengue virus before and who live in areas where this infection is endemic.
Estonian: Dengvaxiat kasutatakse üksnes 9-45-aastastel inimestel, kes on varem dengue viirusega juba nakatunud ja kes elavad piirkondades, kus infektsioon on endeemiline.
English: Available data are not sufficient to confirm how well the vaccine works in individuals previously infected by dengue virus and younger than 9 years.
Estonian: Kättesaadavad andmed ei ole piisavad, et kinnitada, kui hästi vaktsiin toimib varem dengue viirusesse nakatunud alla 9aastastel patsientidel.
English: Therefore, the vaccine should only be given to people who have had a previous dengue infection, as confirmed by laboratory testing.
Estonian: Vaktsiini tuleb seetõttu süstida inimestele, kes on varem dengue viirusesse nakatunud, mida kinnitavad laboriuuringud.
English: For the full list of side effects and restrictions with Dengvaxia, see the package leaflet.
Estonian: Dengvaxia kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Dengue disease is a mosquito-borne tropical disease caused by the dengue virus leading to mild, flulike symptoms in most people.
Estonian: Dengue palavik on sääskede kaudu leviv troopiline haigus, mida põhjustab dengue viirus ja mis tekitab enamikul inimestel kergeid gripilaadseid sümptomeid.
English: Children were given either 3 injections of Dengvaxia or 3 injections of placebo (a dummy vaccine) with 6 months between each injection.
Estonian: Lastele tehti kas 3 Dengvaxia süsti või 3 platseebo (näiv ravim) süsti, mille vahele jäeti 6 kuud.
English: Dengvaxia is effective at reducing the number of cases of dengue disease in people aged between 9 and 45 years who have had the infection in the past.
Estonian: Dengvaxia on dengue palaviku juhtumite arvu vähendamisel efektiivne 9-45aastastel inimestel, kes on varem juba nakatunud.
English: However, among children aged between 9 and 16 years who had not had previous dengue infection, the risk of severe dengue disease if they later became infected with the virus was higher in people vaccinated compared with those given placebo (estimated at 2 additional cases per 1000 people vaccinated over 5 years).
Estonian: Varem viirusesse nakatumata 9-16aastastel lastel oli raske kuluga dengue palaviku risk hilisema viirusesse nakatumise korral suurem, kui neid oli vaktsineeritud, ja väiksem, kui nad olid saanud platseebot (hinnanguliselt 2 lisajuhtumit 100 vaktsineeritud inimese kohta 5 aasta jooksul).
English: Cases of dengue disease were recorded for one year after the last injection.
Estonian: Ühe aasta jooksul alates viimasest süstist registreeriti dengue palaviku juhtumid.
English: How is Dengvaxia used?
Estonian: Kuidas Dengvaxiat kasutatakse?
English: Dengvaxia is a vaccine used to help protect against dengue disease.
Estonian: Dengvaxia on vaktsiin, mida kasutatakse dengue palaviku ennetamiseks.
English: How does Dengvaxia work?
Estonian: Kuidas Dengvaxia toimib?
English: Overall, among children aged between 9 and 16 years and who had previous dengue infection, there were around 79% fewer cases of dengue disease in children vaccinated with 3 doses of Dengvaxia compared with placebo.
Estonian: Üldiselt oli dengue palaviku juhtumeid 9-16aastaste varem dengue viirusega nakatunud laste seas, keda vaktsineeriti 3 annuse Dengvaxiaga, 79% vähem kui platseeborühmas.
English: An overview of Dengvaxia and why it is authorised in the EU
Estonian: Ülevaade ravimist Dengvaxia ja ELis müügiloa väljastamise põhjendus
English: Dengvaxia contains attenuated (weakened) yellow fever viruses that have been manipulated so that they contain proteins from dengue virus.
Estonian: Dengvaxia sisaldab nõrgestatud kollapalaviku viiruseid, mida on muudetud, lisades neile dengue viiruse valke.
English: What benefits of Dengvaxia have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Dengvaxia kasulikkus?
English: Dengvaxia must only be given to people who have had a positive test result showing a previous infection with dengue virus.
Estonian: Dengvaxiat tohib manustada üksnes inimestele, kelle varasem dengue viiruse nakkuse testi tulemus on olnud positiivne.
English: The studies included both children who had and had not been infected with dengue virus in the past.
Estonian: Nendes uuringutes osalesid viirusega varem nakatunud lapsed ning varem nakatumata lapsed.
English: When a person is given the vaccine, the immune system recognises the dengue proteins in the weakened viruses as
Estonian: Vaktsiini manustamisel peab immuunsüsteem nõrgestatud viirustes sisalduvaid dengue viiruse valke võõraiks ja tekitab nende vastu antikehi.
English: Why is Dengvaxia authorised in the EU?
Estonian: ELis Dengvaxiale väljastatud müügiloa põhjendus
English: Immediate Packaging
Estonian: 2 viaali
English: 50 ml (10 mg/ml) 1 vial
Estonian: 1 viaal
English: The educational leaflet shall contain the following key elements:
Estonian: Koolitusjuhendis peab sisalduma alljärgnev oluline teave.
English: The Member States shall ensure that prior to launch the MAH provides health care professionals in dialysis centres and retail pharmacies with:
Estonian: Liikmesriigid peavad tagama, et enne ravimi turustamist varustab müügiloa hoidja dialüüsikeskuste ja jaemüügiapteekide tervishoiutöötajad järgmisega:
English: • Educational leaflet • Summary of product characteristics (SPC) and Package Leaflet and Labelling
Estonian: • koolitusjuhend, • ravimi omaduste kokkuvõte, pakendi infoleht ja pakendi märgistus.
English: CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
Estonian: LIIKMESRIIKIDES RAKENDATAVAD TINGIMUSED VÕI PIIRANGUD, MIS PUUDUTAVAD RAVIMI OHUTUT JA TÕHUSAT KASUTAMIST
English: • The loss of efficacy or other symptoms of the development of immunogenicity should be investigated
Estonian: • Tõhususe puudumist või muid immunogeensuse sümptomeid tuleb uurida.
English: ANNEX CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
Estonian: LISA LIIKMESRIIKIDES RAKENDATAVAD TINGIMUSED VÕI PIIRANGUD, MIS PUUDUTAVAD RAVIMI OHUTUT JA TÕHUSAT KASUTAMIST
English: • There is insufficient data on Epoetin alfa HEXAL to know the size of any increased immunogenicity risk with sc use
Estonian: • Puuduvad piisavad andmed Epoetin alfa HEXALi kohta, et teada ükskõik millise suurenenud immunogeensusohu ulatust ravimi subkutaansel kasutamisel.
English: • That the use of epoetin alfa products can cause immunogenicity which in rare cases may lead to Pure Red Cell Aplasia (PRCA)
Estonian: • Alfaepoetiini sisaldavate ravimite kasutamine võib põhjustada immunogeensust, mis viib harvadel juhtudel isoleeritud erütrotsütaarse aplaasiani.
English: • Therefore, the sc route is not recommended for patients with CKD
Estonian: • Seetõttu ei soovitata ravimi subkutaanset manustamist kroonilise neerupudulikkusega patsientidele.
English: • That with other epoetin products, the risk of immunogenicity in Chronic Kidney Disease (CKD) is increased with the subcutaneous (sc) route.
Estonian: • Teiste epoetiinravimitega suureneb ravimi subkutaansel manustamisel immunogeensusoht kroonilise neerupuudulikkuse korral.
English: • Any suspected case of Pure Red Cell Aplasia or development of immunogenicity should be reported to the MAH
Estonian: • Müügiloa hoidjat tuleb teavitada igast oletatavast isoleeritud erütrotsütaarse aplaasia või immunogeensuse tekkimise juhust.
English: How much to take
Estonian: Kui palju võtta
English: Never take two doses at the same time (morning or evening).
Estonian: Ärge kunagi võtke kahte annust üheaegselt (hommikul ega õhtul).
English: Your body can also make too much sugar.
Estonian: Ka teie organism võib sünteesida liiga palju suhkrut.
English: Multiple-dose study: data are restricted to one study.
Estonian: Mitme annuse uuring: andmed on piiratud ühe uuringuga.
English: Take the medicine pack with you.
Estonian: Võtke ravimipakk kaasa.
English: Due to the limited nature of the data set the results should be interpreted cautiously.
Estonian: Tulenevalt andmekogumi piiratud iseloomust tuleb tulemusi tõlgendada ettevaatusega.
English: - if you have liver problems.
Estonian: - kui teil on probleeme maksaga.
English: These changes are not likely to be clinically meaningful.
Estonian: Need muutused ei ole tõenäoliselt kliiniliselt olulised.
English: The name of your tablet is Jentadueto.
Estonian: Teie tableti nimi on Jentadueto.
English: Date of latest renewal: 22 March 2017
Estonian: Müügiloa viimase uuendamise kuupäev: 22. märts 2017
English: Vitamin B12 deficiency very rare
Estonian: Vitamiin B12 puudulikkus väga harv
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 July 2012
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 20. juuli 2012